Skip to content
Home
Team
Therapies
Overview/Pipeline
IC/BPS
Alenura™
Investor
News
Contact Us
Investor Login
  • February 21, 2023

Vaneltix planning to enroll subjects in new round of clinical trials

Home
/
Uncategorized
/
Vaneltix planning to enroll subjects in new round of clinical trials
Share Post:

On Tuesday, February 21st 2023, Bound Brook, NJ – Vaneltix Pharma, Inc. (Formerly Urigen Pharmaceuticals, Inc.; “Vaneltix” or “the Company”), a specialty pharmaceutical company focused on the development solutions for the five million people with pelvic and bladder pain, announced the the U.S. National Library of Medicine Clinical Trials website has listed Vaneltix’s new round of clinical trials.

Read more: Vaneltix ClinicalTrials.GOV

About Vaneltix

Vaneltix Pharma, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products focused on repurposed products that can be developed through the FDA 505(b)(2) regulatory pathway. Vaneltix’s development programs target significant unmet medical need and major market opportunities in urology and women’s health care. Vaneltix’s lead clinical program is AlenuraTM, a proprietary combination of the approved drugs lidocaine and heparin that is instilled into the bladder, and targets IC/BPS, an unmet medical need which affects at least 6 million 1 men and women in the US. For further information, please visit Vaneltix’s website at http://www.vaneltix.com.

PrevPrevious

Stay Connected

More Updates

Vaneltix enters joint development agreement with Hyloris Pharmaceuticals

On Thursday, December 16, Vaneltix entered into a Joint Development Agreement with Hyloris Pharmaceuticals NV, a Belgian pharmaceuticals company (“Hyloris”) with respect to Vaneltix’s Alenura™

December 21, 2021

Closing of shareholder offering

Vaneltix announces the results of the 2020 Stockholder Offering and Bridge Loan Conversion: The company raised additional proceeds of $900,000 and all the Bridge Loans

November 25, 2020
Vaneltix Pharma, Inc.
305 E High Street, Ste. 7,
Bound Brook, NJ 08805
United States
  • Tel:

    (732) 369-5911
  • Fax:

    (732) 356-1125
  • Email:

    Info@vaneltix.com
Team
Therapies
Investor
News
Contact Us
2021 © Vaneltix. All rights reserved.
Privacy Policy
Privacy Policy
This website is created by Blink.